Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Royalty Pharma Acquires Royalty Interest in Gavreto from Blueprint Medicines for up to USD 340m.

Document Cited in Related
Vincent

MANews-(C)2009-2022

US-based biopharmaceutical royalties buyer Royalty Pharma plc (NASDAQ: RPRX) has acquired an ex-US royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (NASDAQ: BPMC) for up to USD 340m, the company said.

The compensation consists of USD 175m upfront and up to USD 165m in potential sales-based milestones.

Gavreto, marketed by Switzerland-based Roche in certain markets outside the United States and Greater China, is a once-daily rearranged during transfection targeted therapy approved in Europe in November 2021 for the treatment of certain RET-altered non-small cell lung cancers (NSCLC).

Additionally, Gavreto has been submitted for marketing approval for thyroid cancers in Europe with a decision expected in the second half of 2022.

RET activating fusions and mutations are key molecular drivers in multiple cancers and can be identified using diagnostic tests, including next-generation sequencing.

RET fusions are implicated in approximately 1% to 2% of patients with NSCLC, 10% to 20% of patients with papillary thyroid cancer and 90% of patients with advanced medullary...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT